Articles On Immutep (ASX:IMM)

On Tuesday, energy and mining stocks drove gains in the Australian sharemarket. Energy stocks benefited from the rise in oil prices, with West Texas Intermediate trading around $86 per barrel. The avoidance of a Gaza invasion by Tel Aviv te...

The ASX200 lifted nearly 0.2 of a per cent by the end of the day’s session, with materials taking a late run to gain .8 of a per cent. Energy also added almost half a per cent.   Cryptocurrency Bitcoin has also jumped almost 10 per cent...

24 Oct 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Empire Energy (ASX:EEG) and Lincoln Minerals (ASX:LML).

  Immutep (ASX:IMM) has reported promising clinical data from the INSIGHT-003 trial at the ESMO Congress 2023. In response, Immutep CSO, commented, “the compelling data that our proprietary MHC Class II agonist has generated in combination...

The spotlight is on RBA Chief Michele Bullock's speech scheduled for 7pm AEDT at the Global Markets Conference hosted by CBA in Sydney. At noon, the S&P/ASX 200 is 0.22 per cent higher at 6,859.30. The SPI futures are pointing to a rise...

The Australian stock market has given up all of the gains that it had made in 2023, with the benchmark S&P/ASX 200 (INDEXASX: XJO) losing 56.6 points, or 0.8%, on Monday to 6,844.1, with resources weakness the major culprit. That puts t...

Australian company Immutep (ASX:IMM) has announced positive data from a trial of its LAG-3 immunotherapy, eftilagimod alpha, in combination with MSD's KEYTRUDA (pembrolizumab).

The ASX200 closed down .8 of a per cent to a new 100-day low. Energy took the biggest hit – losing three per cent and materials wasn’t much better, shedding 2.3 per cent – while healthcare bucked the trend, adding 1.5 per cent. In the...

Benchmark ASX index closes at new 12-month lows Energy and Materials the worst of 9 dipping ASX sectors on Monday Small caps led by CHM, TON   On Monday Aussie markets rediscovered their nadir of the year. No real surprises, since every n...

Australian shares closed at their lowest level in a year on Monday, following a trend set by a weaker Wall Street. This decline was driven by concerns about an escalation of the Middle East conflict, which negatively impacted investor senti...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, which made announcements today.   ICYMI Lead...

Futures suggested the ASX200 would drop – and it’s dropped almost a per cent, with all sectors in the red, except for healthcare, which has gained nearly a per cent and consumer staples, which has added more than half a per cent. Austral...

Chimeric Therapeutics up 50pc on Phase 1A CLTX CAR T results Immutep up 11pc on TACTI-002/KEYNOTE-798 Phase II trial results ProMedicus signs $16 million, 8-year contract with US hospital   Chimeric jumps 50pc on Phase 1A results Chimeric...

At noon, the S&P/ASX 200 is 0.76 per cent lower at 6,848.40. This drop was in line with Wall Street's performance, driven by concerns about potential interest rate hikes by the Federal Reserve and worries about the escalation of the Mid...

23 Oct 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM; NASDAQ:IMMP), Chimeric Therapeutics (ASX:CHM) and Sayona Mining (ASX:SYA; OTCQB:SYAXF).

  Immutep (ASX:IMM; NASDAQ:IMMP) announced that their Efti, a soluble LAG-3 protein, in Combination with KEYTRUDA®, generates excellent overall survival benefit in patients with metastatic non-small cell lung cancer. In response, Marc Voigt...

Immutep (ASX:IMM) reveals its drug Efti, in combination with Keytruda, generates significant survival benefits for those suffering from metastatic non-small cell lung cancer At lower protein PD-L1 expression, survival rates increase betw...

The Immutep Ltd (ASX: IMM) share price is jumping on Monday. In morning trade, the ASX All Ords biotech stock is up 16% to 32 cents. Why is this ASX All Ords stock racing higher? Investors have been buying the company's shares today follow...

Aussie shares to slump once again after heavy selloff on Wall Street Traders are wary of developments in the Middle East Magnificent Seven to report their earnings this week   Aussie shares are poised to open lower again after another sel...

Welcome to the start of the week. ASX futures were down 65 points (0.95 per cent) heading into 8:30 AEDT. The US had another red session on Friday with the S&P 500 down 1.26 per cent; and the NASDAQ down 1.53 per cent. The Dow and R...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Global Health announces deal with Fujitsu Australia Althea raises $5.32m in sale and leaseback deal Immutep to present data from TACTI-002 in key international forum   Global Health signs with Fujitsu Global Health (ASX:GLH), a provider o...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Consumers are becoming more cautious due to rising living costs, but UBS analysts believe this doesn’t indicate an immediate drop in spending, as they note a slight improvement in future interest rate expectations; however, sticky inflation...

The ASX experienced continued declines at midday, with banking stocks being particularly affected. This drop was triggered by the recent hawkish statements from the US Federal Reserve. At noon, the S&P/ASX 200 is 1.01 per cent lower at...

21 Sep 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Vulcan Energy Resources (ASX:VUL) and Australian Gold and Copper (ASX:AGC).

  Immutep (ASX:IMM; NASDAQ:IMMP) announces the regulatory authorisation of “efti”, which is the Company’s proprietary soluble LAG-3 protein, for the use in clinical trials across multiple European countries. In response, Marc Voigt, CEO of...

ASX to open lower again on Thursday The US Fed held rates steady, but opened the door for one more hike in 2023 Klaviyo (NYSE: KVYO) made its listing debut overnight   Australian shares are poised to track Wall Street and open lower once...

Immutep (ASX:IMM) has announced the regulatory authorisation of eftilagimod alpha manufactured at commercial 2,000L scale for clinical trials across multiple countries, including Germany, Belgium, Denmark, and the UK.

Futures are predicting the market will open slightly lower this morning, despite yesterday’s decision by the US Federal Reserve to hold interest rates steady. The US Fed did state that it could consider another rate hike before the end o...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AMX)) - Aerometrex ((ART)) - Airtasker ((BBT)) - BlueBet Holdings ((CMW)) - Cromwell Property ((DTC)) - Damstra Holdings ((GHY)) - Gold Hydrogen ((IMM)) - Immutep ((LVH)...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

ASX health stocks fall 2.4% in the past five days in line with broader markets Mesoblast crashes more than 50% after US FDA rejects a key product  ImpediMed falls after calls for board spill with discontent following cap raise Healthcare...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Australian clinical-stage biotechnology company Immutep (ASX:IMM) says it has received positive scientific advice from the European Medicines Agency for the continued development of its soluble LAG-3 protein and first-in-class MHC C...

31 Jul 2023 - Immunotherapy company Immutep has released its Quarterly Activities report, which highlights significant progress in late-stage and registrational trials.

Immutep Limited (ASX:IMM; NASDAQ:IMMP), a biotechnology firm specialising in novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, announced its Quarterly Activities Report and Appendix 4C for Q4 FY23. The report...

Australian retail sales experienced a 0.8% decline last month, as reported by the Australian Bureau of Statistics. This result came as a surprise to markets, which had anticipated a steady performance for June following a robust 0.7% gain i...

  First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma Immutep (ASX:IMM; NASDAQ:IMMP) announced that the first patient has been dosed in the Chemotherapy-free Combination Phase II Trial Ta...

The ASX looks set to stoop lower for the last session of the week. Investors are warned to keep an eye open for today’s release of the latest retail sales figures as the rest of Australia prepares for next week’s RBA interest rate decisi...

28 Jul 2023 - A snapshot of the stocks on the move, featuring Immutep (ASX:IMM), Pointerra (ASX:3DP) and Zeus Resources (ASX:ZEU).

ASX healthcare shares are currently underperforming ASX 200 shares, but over the longer term, they’ve grown twice as fast. The S&P/ASX 200 Index (ASX: XJO) is up 7.1% over the past year, while the S&P/ASX 200 Health Care Index (AS...

The All Ordinaries Index (ASX: XAO) is up a healthy 4% in 2023, while ASX All Ords share Immutep Ltd (ASX: IMM) has surged 17% over this same time. And the ASX biotech company could have more potential outperformance to come. Here’s w...

The Bubs Australia Ltd (ASX: BUB) share price is ending the week deep in the red. In morning trade, the embattled infant formula company’s shares are down 11% to 16 cents. Why is the Bubs share price sinking? Investors have been hitting...

ASX 200 benchmark climbs 0.65% despite a sour lead-in from Wall Street and Europe. Real Estate sector banks solid wins after shopping centres put on a big day.  Forrestania Resources hits 162% on thick pegmatite news, but the ASX has asked...

  Marc Voigt – Executive Director & CEO – Immutep (ASX:IMM) is a clinical-stage biotechnology company at the forefront of developing novel LAG-3 immunotherapy for cancer and autoimmune diseases.

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...